Cubist Systematic Strategies LLC Reduces Stock Position in QIAGEN N.V. $QGEN

Cubist Systematic Strategies LLC decreased its stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 35.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,385 shares of the company's stock after selling 25,043 shares during the period. Cubist Systematic Strategies LLC's holdings in QIAGEN were worth $1,862,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in QGEN. Price T Rowe Associates Inc. MD lifted its position in QIAGEN by 3,030.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock valued at $179,501,000 after purchasing an additional 4,327,934 shares during the period. Wellington Management Group LLP raised its position in QIAGEN by 12.2% in the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock worth $972,191,000 after acquiring an additional 2,656,136 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in QIAGEN in the fourth quarter worth approximately $95,746,000. Deutsche Bank AG raised its position in QIAGEN by 57.5% in the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the period. Finally, Nuveen LLC bought a new position in QIAGEN in the first quarter worth approximately $44,078,000. Institutional investors own 70.00% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on QGEN shares. UBS Group increased their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Wall Street Zen cut shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Cowen reissued a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Bank of America increased their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Finally, Barclays initiated coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, QIAGEN presently has an average rating of "Hold" and a consensus price target of $49.69.

QIAGEN Price Performance

QGEN traded down $0.76 during trading on Friday, hitting $45.30. 992,179 shares of the company traded hands, compared to its average volume of 1,319,392. The company has a market cap of $10.07 billion, a PE ratio of 26.76, a P/E/G ratio of 2.43 and a beta of 0.64. The stock's 50-day simple moving average is $48.47 and its two-hundred day simple moving average is $44.59. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. QIAGEN's quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the company posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, sell-side analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.